Skip to main content
. Author manuscript; available in PMC: 2014 Mar 15.
Published in final edited form as: Cancer Res. 2013 Jan 14;73(6):1668–1675. doi: 10.1158/0008-5472.CAN-12-3810

Fig. 1. Trp53null hosts augment tolerogenic tumor microenvironment and promote tumor progression.

Fig. 1

WT and p53null C57/B6 mice were inoculated subcutaneously with 2 × 105 B16F1 cells. (A) Tumor size was measured every other day (n=10 - 15). (B) Mice were euthanized on day18 post-inoculation. CD4+, CD8+, CD49b+, and CD11b+ cells among tumor infiltrating leukocytes (TIL, CD45+) were examined. (C) The percentage of effector cytokine producing TIL-CD4 and (D) FoxP3+ regulatory T cells was determined. Results are presented as mean ± standard error (s.e.) of 5 – 10 mice from at least three independent experiments. * represents a significant difference (p < 0.05). Two-tailed Student’s t-test.